Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakakibara-Konishi, Jun, Sato, Mineyoshi, Sato, Michiko Takimoto, Kasahara, Kohei, Onozawa, Masahiro, Mizugaki, Hidenori, Kikuchi, Eiki, Asahina, Hajime, Shinagawa, Naofumi, Konno, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378269/
https://www.ncbi.nlm.nih.gov/pubmed/32714828
http://dx.doi.org/10.1016/j.rmcr.2020.101170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378269/
https://www.ncbi.nlm.nih.gov/pubmed/32714828
http://dx.doi.org/10.1016/j.rmcr.2020.101170

Ejemplares similares